vs

Side-by-side financial comparison of MEDALLION FINANCIAL CORP (MFIN) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

MEDALLION FINANCIAL CORP is the larger business by last-quarter revenue ($70.6M vs $35.5M, roughly 2.0× RECURSION PHARMACEUTICALS, INC.). MEDALLION FINANCIAL CORP runs the higher net margin — 17.3% vs -304.2%, a 321.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 25.4%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 15.0%).

Mahindra & Mahindra Financial Services Limited (MMFSL) is an Indian rural non-banking financial company headquartered in Mumbai. It is amongst the top tractor financers in India, with 1000+ offices across the country.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MFIN vs RXRX — Head-to-Head

Bigger by revenue
MFIN
MFIN
2.0× larger
MFIN
$70.6M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+656.3% gap
RXRX
681.7%
25.4%
MFIN
Higher net margin
MFIN
MFIN
321.5% more per $
MFIN
17.3%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
15.0%
MFIN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MFIN
MFIN
RXRX
RXRX
Revenue
$70.6M
$35.5M
Net Profit
$12.2M
$-108.1M
Gross Margin
59.8%
Operating Margin
29.3%
-304.8%
Net Margin
17.3%
-304.2%
Revenue YoY
25.4%
681.7%
Net Profit YoY
20.3%
39.6%
EPS (diluted)
$0.50
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MFIN
MFIN
RXRX
RXRX
Q4 25
$70.6M
$35.5M
Q3 25
$58.7M
$5.2M
Q2 25
$62.6M
$19.2M
Q1 25
$63.0M
$14.7M
Q4 24
$56.3M
$4.5M
Q3 24
$53.3M
$26.1M
Q2 24
$51.0M
$14.4M
Q1 24
$53.3M
$13.8M
Net Profit
MFIN
MFIN
RXRX
RXRX
Q4 25
$12.2M
$-108.1M
Q3 25
$7.8M
$-162.3M
Q2 25
$11.1M
$-171.9M
Q1 25
$12.0M
$-202.5M
Q4 24
$10.1M
$-178.9M
Q3 24
$8.6M
$-95.8M
Q2 24
$7.1M
$-97.5M
Q1 24
$10.0M
$-91.4M
Gross Margin
MFIN
MFIN
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
MFIN
MFIN
RXRX
RXRX
Q4 25
29.3%
-304.8%
Q3 25
33.2%
-3327.6%
Q2 25
31.1%
-916.8%
Q1 25
32.1%
-1297.9%
Q4 24
32.8%
-4042.4%
Q3 24
26.6%
-377.1%
Q2 24
24.3%
-697.4%
Q1 24
33.6%
-698.4%
Net Margin
MFIN
MFIN
RXRX
RXRX
Q4 25
17.3%
-304.2%
Q3 25
13.2%
-3135.3%
Q2 25
17.7%
-894.2%
Q1 25
19.1%
-1373.3%
Q4 24
18.0%
-3935.5%
Q3 24
16.1%
-367.5%
Q2 24
13.9%
-676.6%
Q1 24
18.8%
-662.4%
EPS (diluted)
MFIN
MFIN
RXRX
RXRX
Q4 25
$0.50
$-0.17
Q3 25
$0.32
$-0.36
Q2 25
$0.46
$-0.41
Q1 25
$0.50
$-0.50
Q4 24
$0.43
$-0.56
Q3 24
$0.37
$-0.34
Q2 24
$0.30
$-0.40
Q1 24
$0.42
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MFIN
MFIN
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$136.3M
$743.3M
Total DebtLower is stronger
$216.0M
$9.6M
Stockholders' EquityBook value
$408.6M
$1.1B
Total Assets
$3.0B
$1.5B
Debt / EquityLower = less leverage
0.53×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MFIN
MFIN
RXRX
RXRX
Q4 25
$136.3M
$743.3M
Q3 25
$72.5M
$659.8M
Q2 25
$110.4M
$525.1M
Q1 25
$131.5M
$500.5M
Q4 24
$98.2M
$594.4M
Q3 24
$120.6M
$427.6M
Q2 24
$87.7M
$474.3M
Q1 24
$54.8M
$296.3M
Total Debt
MFIN
MFIN
RXRX
RXRX
Q4 25
$216.0M
$9.6M
Q3 25
$215.7M
$11.9M
Q2 25
$199.9M
$14.2M
Q1 25
$199.7M
$16.4M
Q4 24
$232.2M
$19.0M
Q3 24
$232.0M
$20.5M
Q2 24
$230.8M
$22.9M
Q1 24
$225.6M
Stockholders' Equity
MFIN
MFIN
RXRX
RXRX
Q4 25
$408.6M
$1.1B
Q3 25
$397.4M
$1.0B
Q2 25
$389.9M
$919.1M
Q1 25
$380.2M
$933.9M
Q4 24
$370.2M
$1.0B
Q3 24
$362.4M
$524.6M
Q2 24
$354.0M
$584.4M
Q1 24
$349.0M
$401.2M
Total Assets
MFIN
MFIN
RXRX
RXRX
Q4 25
$3.0B
$1.5B
Q3 25
$2.9B
$1.4B
Q2 25
$2.9B
$1.3B
Q1 25
$2.8B
$1.3B
Q4 24
$2.9B
$1.4B
Q3 24
$2.9B
$726.5M
Q2 24
$2.8B
$775.9M
Q1 24
$2.6B
$557.8M
Debt / Equity
MFIN
MFIN
RXRX
RXRX
Q4 25
0.53×
0.01×
Q3 25
0.54×
0.01×
Q2 25
0.51×
0.02×
Q1 25
0.53×
0.02×
Q4 24
0.63×
0.02×
Q3 24
0.64×
0.04×
Q2 24
0.65×
0.04×
Q1 24
0.65×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MFIN
MFIN
RXRX
RXRX
Operating Cash FlowLast quarter
$126.3M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
10.35×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MFIN
MFIN
RXRX
RXRX
Q4 25
$126.3M
$-46.1M
Q3 25
$67.0M
$-117.4M
Q2 25
$-10.7M
$-76.4M
Q1 25
$36.3M
$-132.0M
Q4 24
$108.7M
$-115.4M
Q3 24
$24.6M
$-59.2M
Q2 24
$27.6M
$-82.2M
Q1 24
$32.3M
$-102.3M
Free Cash Flow
MFIN
MFIN
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
MFIN
MFIN
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
MFIN
MFIN
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
MFIN
MFIN
RXRX
RXRX
Q4 25
10.35×
Q3 25
8.63×
Q2 25
-0.97×
Q1 25
3.02×
Q4 24
10.72×
Q3 24
2.86×
Q2 24
3.89×
Q1 24
3.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons